Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747513 | 0.82 | ELANE (0.32) | BRD4ELANEALDH1A1ESR2 | |
| SCHEMBL4069127 | 0.81 | PDE7A (0.33) | BRD4ELANEALDH1A1ESR2 | |
| SCHEMBL147830 | 0.80 | BRD4 (0.51) | BRD4CYP1A2CYP2A6L3MBTL1 | |
| SCHEMBL10234059 | 0.80 | BRD4 (0.43) | BRD4CYP1A2CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL19001036 | 0.76 | GABRA1 (0.36) | BRD4ELANEALDH1A1L3MBTL1 | |
| SCHEMBL29712379 | 0.74 | CYP1A2 (0.41) | CYP1A2CYP2A6ALDH1A1LMNAKDM4E | |
| SCHEMBL19012502 | 0.73 | FAAH (0.34) | ELANECYP1A2ALDH1A1LMNAKDM4E | |
| SCHEMBL4076792 | 0.72 | KMT2A (0.41) | ELANECYP1A2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10232908 | 0.72 | BRD4 (0.41) | BRD4CYP1A2CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL13083322 | 0.72 | KAT2B (0.37) | BRD4CYP1A2CYP2A6ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8110674-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | BRD4 2842/4885ELANE 718/4885CYP1A2 4804/4885 |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | BRD4 2399/4885ELANE 289/4885CYP1A2 4881/4885 |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | BRD4 2399/4885ELANE 289/4885CYP1A2 4881/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | BRD4 2420/4885ELANE 578/4885CYP1A2 3847/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | BRD4 2743/4885ELANE 2689/4885CYP1A2 4840/4885 |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | IFNAR1, DDX18, STING1 | BRD4 4340/4885ELANE 1928/4885CYP1A2 2784/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | BRD4 1591/4885ELANE 2998/4885CYP1A2 4371/4885 |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | BRD4 727/4885ELANE 1438/4885CYP1A2 4378/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | BRD4 2305/4885ELANE 1838/4885CYP1A2 3615/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | BRD4 2420/4885ELANE 1776/4885CYP1A2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.